Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.
Also called NCT02836873
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 312 participants
- Sponsor
- Registry
-
NCT02836873
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, France, Japan, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02836873. Randomized; triple masking; primary purpose treatment. Start 2016-09-23 (actual); primary completion 2018-01-11 (actual). Results posted on 2021-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Bexagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Theracos
Record details
- Record id
cardio:ct-nct02836873- Content hash
e6a322382fb77aae16d26643dc27a8b9f3b05519faf5146b4248b97f1b4b0361